help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism Vol. 50, No. 1 23-26
doi:10.1210/jcem-50-1-23
Copyright © 1980 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FERRARI, C.
Right arrow Articles by TELLOLI, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FERRARI, C.
Right arrow Articles by TELLOLI, P.

Failure of Nomifensine Administration to Discriminate between Tumorous and Nontumorous Hyperprolactinemia*

C. FERRARI, P. G. CROSIGNANI, R. CALDARA, M. C. PICCIOTTI, A. MALINVERNI, B. BARATTINI, P. RAMPINI and P. TELLOLI

Second Department of Medicine, Fatebenefratelli Hospital, and the Department of Obstetrics and Gynecology, University of Milan Milan, Italy

Address requests for reprints to: P. G. Crosignani, M.D., IV Clinica Ostetrica e Ginecologica, Universita di Milano, 12 Via Commenda, 20122 Milano, Italy

It has recently been claimed that the PRL-lowering response to nomifensine administration (200 mg, orally) reliably discriminates patients with PRL-secreting tumors from those with so-called functional hyperprolactinemia. In the present study, this test was performed in 15 healthy controls, 7 hyperprolactinemic subjects without evidence of pituitary tumor, and 16 patients with prolactinoma. A decrease of serum PRL to below 65% of basal levels, which seemed to be the cutoff point in the previous study, was obtained in 11 subjects of the first group, in 4 subjects of the second group, and in 4 subjects of the third group. The decrease of mean serum PRL concentration after nomifensine was only significant in the first and second groups. Analysis of variance showed a significant difference in the PRL inhibition by nomifensine between the tumor group and the two groups without evidence of pituitary adenoma. Nevertheless, this study shows that the nomifensine test is unable to discriminate in the individual patient the tumorous or nontumorous origin of excessive PRL secretion.

* This work was supported in part by a C.N.R. Special Program, Control of Neoplastic Growth.

Received June 6, 1979.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society